Seralutinib

N/A

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameSeralutinib
Drug Alias NamePK-10571GB-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionStem cell growth factor receptor inhibitorsGranulocyte-macrophage colony-stimulating factor receptor antagonistsPlatelet-derived growth factor receptor beta inhibitors +[5] 
TargetsPlatelet-derived growth factor receptorColony stimulating factor 1 receptorStem cell growth factor receptor +[6] 
Therapy Area/IndicationsPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesGb002, Inc
Inactive CompaniesChiesi Farmaceutici SPA
Active IndicationsPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG